Abstract: Stabilized multi-component antimicrobial compositions for treating tissue diseases, infections or conditions include a first and second set of differently sized and/or differently shaped metal nanoparticles, and a stabilizing agent. Compositions and treatment methods may be used for treating tissue diseases, infections or conditions caused by microbial infections, such as bacteria, viral, and/or fungal infections, or for preventing the infection of a wound, such as a cut, abrasion, ulcer, lesion, sore, and the like. The compositions and treatment methods disclosed herein may also be used as a prophylactic, and in some embodiments may be applied to otherwise healthy tissue in order to prevent or reduce the occurrence of a tissue disease, infection or condition.
Type:
Grant
Filed:
November 29, 2017
Date of Patent:
March 23, 2021
Assignee:
ATTOSTAT, INC.
Inventors:
Bryon J. Tarbet, William H. Niedermeyer
Abstract: The present invention is directed to pharmaceutical compositions comprising melphalan and a cyclodextrin derivative, and methods of making and using the same.
Abstract: This invention relates to a hemostatic member using chitosan having superior hemostatic activity, and more particularly to a chitosan-based hemostatic member for the cervix, suitable for use through insertion into an affected part upon cervical biopsy or surgery, configured to include a hemostatic pack having a projection at an upper end thereof through tying with a thread so as to form a spherical shape using chitosan nonwoven fabrics having a hemostatic function, wherein the thread contains an X-ray-sensitive material, thereby realizing effective hemostasis of the affected part upon cervical biopsy or surgery.
Abstract: Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent.
Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
Abstract: Provided herein are compositions useful for treating inflammation in a subject and methods of decreasing inflammation in the skin, mucosa, and/or eye of a subject comprising applying a pharmaceutical composition that includes an NO-releasing compound to the skin, mucosa, and/or eye of the subject in an amount sufficient to decrease inflammation.
Type:
Grant
Filed:
March 2, 2017
Date of Patent:
February 9, 2021
Assignee:
Novan, Inc.
Inventors:
Nathan Stasko, Ryan Doxey, Kimberly McHale, Stanley J. Hollenbach
Abstract: According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.
Abstract: Provided herein are methods for maintaining physiological levels of nitrite in a subject undergoing hemodialysis. Also provided herein are methods of administering pharmaceutically acceptable sodium nitrite to a subject undergoing hemodialysis.
Abstract: The present invention relates to biomaterials coated with an active agent eluting coating, wherein implantation of the coated biomaterial results in reduced implant-related complications and/or improved integration of the biomaterial into the host tissue and further relates to kits containing the coated biomaterial. The present invention also relates to methods and kits for coating the biomaterial. It is based, at least in part, on the discovery that biomaterial coated with a cytokine eluting coating resulted in the shift of early stage macrophage polarization that were associated with positive long-term effects such as minimized capsule formation and improved tissue quality and composition as compared to uncoated biomaterials.
Type:
Grant
Filed:
January 13, 2020
Date of Patent:
January 12, 2021
Assignee:
UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Inventors:
Bryan Nicklaus Brown, Daniel Jordi Hachim Diaz
Abstract: The instant disclosure relates to an integral porous fiber media with distinguishable distribution of fiber density, fiber diameter and capillary force. The instant disclosure further relates to a fiber porous media that includes multiple density portions. The disclosed media is a single piece, such that the different density portions are not separable. The disclosed media provides improved liquid delivery properties for a specific liquid delivery device.
Type:
Grant
Filed:
May 31, 2018
Date of Patent:
January 5, 2021
Assignee:
POREX TECHNOLOGIES CORPORATION
Inventors:
David Harris, Yelena Rogova, Qiang Zhou, Guoqiang Mao
Abstract: Aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine to a subject diagnosed as having ADHD, anxiety or insomnia. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in the subject. Also provided are transdermal delivery devices configured to deliver an amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.
Abstract: This invention provides a groundbreaking approach to PLNPs and their preparation. In particular, the synthetic methodology disclosed herein fundamentally differs from the traditional solid-state annealing reactions that require extreme and harsh reaction conditions. In one unique aspect of the invention, a simple, one-step mesoporous template method utilizing mesoporous silica nanoparticles (MSNs) is disclosed that affords in vivo rechargeable NIR-emitting mesoporous PLNPs with uniform size and morphology. In another unique aspect of the invention, the novel synthetic approach is based on aqueous-phase chemical reactions conducted in mild conditions, resulting in uniform and homogeneous PLNPs with desired size control (e.g., sub-10 nm).
Abstract: The present disclosure is directed to pharmaceutical compositions comprising a nitrogen mustard and a cyclodextrin derivative, and methods of making and using the same.
Abstract: Pharmaceutical compositions of muscarinic acetylcholine receptor antagonists suitable for administration via a dry powdered inhaler and methods of using the compositions for treating respiratory disease are provided.
Type:
Grant
Filed:
January 7, 2017
Date of Patent:
November 17, 2020
Assignee:
THERON PHARMACEUTICALS, INC.
Inventors:
Meenakshi S. Venkatraman, Xiaoming Zhang, Phillip Haywood
Abstract: The present disclosure relates to compositions useful in synthetic bone graft applications. Particularly, the disclosure teaches moldable bone graft compositions, methods of making said compositions, and methods of utilizing the same.
Type:
Grant
Filed:
July 27, 2018
Date of Patent:
November 17, 2020
Assignee:
Bioventus, LLC
Inventors:
John E. Brunelle, Russell L. Cook, Duraid S. Antone
Abstract: The present invention belongs to the area of body odour modelling. In particular, the developed synthetic compositions of the present invention reconstitute human body odours, especially those arising from axillary perspiration. The use of the compositions herein allows for the evaluation of malodour masking effects of fragrant compositions in the field of personal care or homecare products and cosmetic product development.
Type:
Grant
Filed:
October 22, 2015
Date of Patent:
November 10, 2020
Assignees:
Symrise AG, Monell Chemical Senses Center
Inventors:
Marco Singer, Keith McDermott, Marcela Olalde-Castillo, George Preti, Charles Wysocki, Katherine Ashley Prigge
Abstract: Provided is a transdermal absorption sheet capable of improving strength against impact at the time of puncture. A transdermal absorption sheet includes a sheet portion and a plurality of needle-like protruding portions arranged on a first principal surface of the sheet portion, in which the sheet portion has a center portion which is a region in which the plurality of needle-like protruding portions are formed, and an outer edge portion which is a region from the center portion to an end portion, and a maximum thickness of a thickness portion of the outer edge portion is larger than an average thickness of the center portion.
Abstract: Provided is a bioimplant which is capable to inhibit the biofilm formation over a long period of time after an operation. The bioimplant of the present invention comprises a base material of metal, ceramic, or plastic and a thermal spraying film of a calcium phosphate-based material formed at least partially thereon and the silver concentration in the thermal-spray film is 0.05 wt % to 3.00 wt %.
Abstract: A method of treating a spinal disk according to the present invention can include inserting an alloplastic bulking agent into the spinal disk to treat the defect. The alloplastic bulking agent has a plurality of microparticles and a suspending agent comprising hyaluronic acid. The bulking agent results in at least one of sealing the defect, increasing a pressure of the disk, increasing a height of the disk, improving stability of the disk and improving structural integrity of the disk.
Type:
Grant
Filed:
March 22, 2019
Date of Patent:
October 20, 2020
Assignee:
SpineOvations, Inc.
Inventors:
Stuart Young, Neville Alleyne, Nicholas John Manesis
Abstract: Cationically-charged particulates and compositions containing the cationically-charged particulates for application to keratinous materials are provided. Methods of preparing the cationically-charged particulates are also disclosed. Methods of increasing the cationic charge on particulates are also provided.